Xintela AB Interim Report January – September 2022
Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. Third quarter 2022 for the group» Income amounted to TSEK 0 (0)» Loss before and after tax totalled TSEK 14,456 (loss: 15,892)» Loss per share* was SEK 0.11 (loss: 0.20) First nine months 2022 for the group» Income […]
Targinta plans Phase 0 clinical study
Targinta’s Board of Directors has decided to focus development of the company’s therapeutic antibodies on a so-called clinical Phase 0 study (microdosing study) in cancer patients. The purpose of the clinical Phase 0 study is to show, with a very low dose of labeled antibodies, that they target the tumor and thus validate Targinta’s proprietary […]
Xintela starts next dose level of XSTEM in knee osteoarthritis clinical study
Xintela’s first-in-human study (Phase I/IIa) for the treatment of knee osteoarthritis, being conducted in Australia, is testing 3 different dose levels of the stem cell product XSTEM®. The Safety Review Committee for the clinical study assessed the treatment of the eight patients on the lowest XSTEM dose level at the one-month follow-up, concluded the dose […]
Xintela proposes Thomas Eldered as new Board member
Major shareholder in Xintela AB (publ) proposes that the company’s shareholders elect Thomas Eldered as a new member of the Board at the Extra General Meeting on November 28, 2022. The board of directors announces the proposal regarding election of new Board member at the Extra General Meeting on November 28, 2022. The company’s major […]
Xintela completes dosing of XSTEM first dose level in knee osteoarthritis clinical study
Xintela’s first-in-human study (Phase I/IIa) for the treatment of knee osteoarthritis, being conducted in Australia, is testing 3 different dose levels of the stem cell product XSTEM®. All patients at the lowest dose level have now been dosed. XSTEM, which consists of allogeneic (donated) integrin α10β1-selected mesenchymal stem cells, is developed and manufactured by Xintela. […]
Targinta appoints Peter Ekolind as acting CEO
Targinta’s board has appointed Peter Ekolind as acting CEO, starting from October 1, 2022, as a part-time assignment, due to Per Norlén’s resignation as CEO. Peter Ekolind has more than 30 years of experience from operational and strategic positions at management level in the pharmaceutical and medical technology industry, from multinational companies to small development […]
Xintela starts clinical study with XSTEM for difficult-to-heal leg ulcers
Xintela starts its second clinical study (Phase I/IIa) with XSTEM® for the treatment of difficult-to-heal venous leg ulcers. XSTEM, which consists of allogeneic (donated) integrin α10β1-selected mesenchymal stem cells, is developed and manufactured by Xintela. The recruitment of patients for the Phase I/IIa study for the treatment of difficult-to-heal venous leg ulcers, which is carried […]
Targinta presents positive preclinical data on the antibody-drug conjugate TARG9
The oncology company Targinta, a wholly owned subsidiary of Xintela AB (publ), presents new preclinical data on the antibody-drug conjugate TARG9 at the 2nd Integrin-Targeted Drug Development Summit, Boston, on September 1, 2022 at 11 a.m. local time (17:00 CEST). Targinta develops first-in-class tumor-targeting antibodies and antibody-drug conjugates (ADCs) against the unique and patent protected […]
Xintela AB Interim Report January – June 2022
Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. Second quarter 2022 for the group» Income amounted to TSEK 0 (0).» Loss before tax totalled TSEK 18,942 (loss: 15,020).» Loss per share was SEK 0.21 (loss: 0.17). First half year 2022 for the group» Income amounted to […]
Per Norlén to step down as Targinta CEO
Targinta announces that Per Norlén will leave his position as CEO of the company effective late January 2023 at the latest to take on the CEO role in another drug development company. “We have started the work of recruiting a new CEO for Targinta. In the meantime, Per will continue to support Targinta’s development activities. […]
